NO964628L - DNA-sekvenser - Google Patents

DNA-sekvenser

Info

Publication number
NO964628L
NO964628L NO964628A NO964628A NO964628L NO 964628 L NO964628 L NO 964628L NO 964628 A NO964628 A NO 964628A NO 964628 A NO964628 A NO 964628A NO 964628 L NO964628 L NO 964628L
Authority
NO
Norway
Prior art keywords
aberrant splicing
mrna nucleotide
dna sequences
sites
expression
Prior art date
Application number
NO964628A
Other languages
English (en)
Other versions
NO964628D0 (no
Inventor
Anthony John Clark
Original Assignee
Ppl Therapeutics Scotland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ppl Therapeutics Scotland Ltd filed Critical Ppl Therapeutics Scotland Ltd
Publication of NO964628D0 publication Critical patent/NO964628D0/no
Publication of NO964628L publication Critical patent/NO964628L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/644—Coagulation factor IXa (3.4.21.22)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21022—Coagulation factor IXa (3.4.21.22)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Dårlige ekspresjonsutbytter av rekombinant, human faktor IX skyldes avvikende spleising i heterologe ekspresjonssystemer, slik som transgene verter. De avvikende spleisingsseter er identifisert som (a) et donorsete om- fattende mRNA-nukleotid 1085; og (b) et akseptorsete omfattende mRNA-nukleotid 1547; når man velger å bruke mRNA- nukleotidnummereringen ifølge figur 2 i figurene. Forbedrede faktor IX-ekspre- sjonssekvenser har minst ett av disse setene konstruert bort, for å forebygge eller redusere virkningen av avvikende spleising, og for å øke utbytter. De forbedrede DNA-sekvensene kan også være anvendbare ved genterapi.
NO964628A 1994-05-03 1996-11-01 DNA-sekvenser NO964628L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9408717A GB9408717D0 (en) 1994-05-03 1994-05-03 DNA sequences
PCT/GB1995/000996 WO1995030000A1 (en) 1994-05-03 1995-05-02 Dna sequences

Publications (2)

Publication Number Publication Date
NO964628D0 NO964628D0 (no) 1996-11-01
NO964628L true NO964628L (no) 1997-01-03

Family

ID=10754465

Family Applications (1)

Application Number Title Priority Date Filing Date
NO964628A NO964628L (no) 1994-05-03 1996-11-01 DNA-sekvenser

Country Status (11)

Country Link
US (1) US6046380A (no)
EP (1) EP0763108A1 (no)
JP (1) JPH09512430A (no)
CN (1) CN1149317A (no)
AU (1) AU686375B2 (no)
CA (1) CA2189438A1 (no)
FI (1) FI964423A0 (no)
GB (1) GB9408717D0 (no)
NO (1) NO964628L (no)
NZ (1) NZ284550A (no)
WO (1) WO1995030000A1 (no)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5744326A (en) * 1996-03-11 1998-04-28 The Immune Response Corporation Use of viral CIS-acting post-transcriptional regulatory sequences to increase expression of intronless genes containing near-consensus splice sites
ATE336585T1 (de) * 1996-06-27 2006-09-15 Novozymes Inc Modifikation von kryptischen splicemotiven heterologer gene zur expression in pilzen
DE69841459D1 (en) * 1997-02-14 2010-03-11 American Nat Red Cross Expression des active human factor ix im brustdrüsengewebe transgener tiere
US6231863B1 (en) * 1997-06-10 2001-05-15 American Cyanamid Company DNA sequences, molecules, vectors and vaccines for feline calicivirus disease and methods for producing and using same
AU735763B2 (en) * 1997-12-05 2001-07-12 Immune Response Corporation, The Novel vectors and genes exhibiting increased expression
GB9908788D0 (en) * 1999-04-16 1999-06-09 Univ London Gene expression in eukaryotic cells
US6936467B2 (en) * 2000-03-27 2005-08-30 University Of Delaware Targeted chromosomal genomic alterations with modified single stranded oligonucleotides
AU2001263271A1 (en) * 2000-05-17 2001-11-26 University Of Delaware Plant gene targeting using oligonucleotides
WO2002077161A2 (en) * 2001-03-12 2002-10-03 Progenetics Llc Production of high levels of trangenic factor ix without gene rescue, and its therapeutic uses
US20040133930A1 (en) 2002-03-11 2004-07-08 Cooper Julian D. Production of high levels of transgenic factor ix without gene rescue, and its therapeutic uses
CA2448109A1 (en) * 2001-05-25 2002-12-05 Thomas Jefferson University Alternative splice forms of proteins as basis for multiple therapeutic modalities
US7220718B2 (en) * 2001-08-03 2007-05-22 United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Oral treatment of hemophilia
WO2004099231A2 (en) 2003-04-09 2004-11-18 Neose Technologies, Inc. Glycopegylation methods and proteins/peptides produced by the methods
EP2305314B1 (en) 2001-10-10 2015-12-23 ratiopharm GmbH Remodelling and glycoconjugation of antibodies
EP2279755B1 (en) 2001-10-10 2014-02-26 ratiopharm GmbH Remodelling and glycoconjugation of Fibroblast Growth Factor (FGF)
US20080255026A1 (en) 2005-05-25 2008-10-16 Glycopegylated Factor 1X Glycopegylated Factor Ix
FR2901707B1 (fr) 2006-05-31 2017-09-29 Lab Francais Du Fractionnement Composition de facteur vii recombinant ou transgenique, chaque molecule de facteur vii possedant deux sites de n-glycosylation a motifs glycanniques definis
FR2904558B1 (fr) * 2006-08-01 2008-10-17 Lab Francais Du Fractionnement "composition de facteur vii recombinant ou transgenique, presentant majoritairement des formes glycanniques biantennees, bisialylees et non fucosylees"
FR2910786B1 (fr) * 2006-12-29 2017-08-11 Laboratoire Francais Du Fractionnement Et Des Biotechnologies (Lfb) "procede d'extraction d'une proteine presente dans du lait"
FR2912310B1 (fr) 2007-02-13 2009-08-07 Kasan Sarl Nouvelles compositions cosmetiques et/ou pharmaceutiques et leurs applications.
KR101190605B1 (ko) * 2007-06-15 2012-10-15 재단법인 목암생명공학연구소 활성형 재조합 혈액응고 9인자의 대량생산 방법
DK3581650T3 (da) 2008-09-15 2023-03-13 Uniqure Biopharma B V Faktor ix polypeptidmutant, anvendelse deraf og en fremgangsmåde til fremstilling deraf
US8861162B2 (en) * 2010-03-09 2014-10-14 Honeywell International Inc. High power solid state power controller (SSPC) solution for primary power distribution applications
BR112021007301A2 (pt) 2018-10-18 2021-07-27 Intellia Therapeutics, Inc. composições e métodos para expressar fator ix

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9028062D0 (en) * 1990-12-24 1991-02-13 Agricultural & Food Res Production of transgenic animals

Also Published As

Publication number Publication date
AU2317095A (en) 1995-11-29
FI964423A (fi) 1996-11-04
US6046380A (en) 2000-04-04
WO1995030000A1 (en) 1995-11-09
CA2189438A1 (en) 1995-11-09
EP0763108A1 (en) 1997-03-19
NZ284550A (en) 1998-05-27
NO964628D0 (no) 1996-11-01
GB9408717D0 (en) 1994-06-22
CN1149317A (zh) 1997-05-07
JPH09512430A (ja) 1997-12-16
FI964423A0 (fi) 1996-11-04
AU686375B2 (en) 1998-02-05

Similar Documents

Publication Publication Date Title
NO964628L (no) DNA-sekvenser
WO1995032298A3 (en) Safe vectors for gene therapy
AU1441900A (en) Gene delivery system and methods of use
ATE304604T1 (de) Adenovirus vektoren für gentherapie
DK0770136T3 (da) Fremgangsmåde til at selektere höjtudtrykkende værtsceller
CY1106216T1 (el) 5´ ESTs ΓΙΑ ΜΗ ΙΣΤΟ-ΕΙΔΙΚΕΣ ΕΚΚΡΙΤΙΚΕΣ ΠΡΩΤΕΪΝΕΣ
EP0710288A4 (en) ADENOVIRAL VECTORS FOR TREATMENT OF HEMOPHILIA
GB2136814B (en) Dna vectors
NO954132L (no) Defektive rekombinant-adenoviruser for genterapi av tumorer
EP1803815A3 (de) Starker homologer Promotor aus Hamster
DE69635931D1 (de) Komplementäre adenovirenvektorsysteme und zellinien
CA2213343A1 (en) Chimeric adenoviral fiber protein and methods of using same
IL181695A0 (en) Methods for cultivating cells and propagating viruses
DE69319972T2 (de) Hyperthermophilische alpha-amylase Gene
ATE271607T1 (de) Vorbeugen des graftsabstosses in transplantaten und zur herstellung von universalen gentherapie wirtszell, unter anwendung von lymphozytenaktivierungsgen-3 (lag-3)
IL90334A0 (en) Genetic transformation of b.thuringiensis,vectors used therefor,host cells transformed by the vectors and use of said cells as insecticides
CA2309600A1 (en) Low-temperature inducible expression vector
ATE412058T1 (de) Interne ribosomenzugangsstelle-enthaltende zell- spezifische adenovirale vektoren
WO1998010085A3 (en) Gene therapy for congestive heart failure
NO974179D0 (no) Rekombinante viruser som uttrykker lecitin-kolesterol-acyltransferase, og anvendelse derav i genterapi
DE60031369D1 (de) Replikation -defektive baculoviren expressionssystem
DK0627004T3 (da) Forbedringer ved eller i forbindelse med malariavaccine
FI953094A (fi) Neutraali itsekiillottuva emulsio lattioiden hoitoon (I)
BR0015784A (pt) Promotor e ìntron do fator de despolimerização de actina de milho
FI964784A0 (fi) Yhdistelmä-DNA-viruksia, valmistus ja käyttö geeniterapiassa